US biotech companies Biogen and Sage Therapeutics have announced that Zurvuvae (zuranolone) is now available by prescription for the treatment of postpartum dep 14 December 2023
American healthcare giant Johnson & Johnson has undertaken an in-depth business review, publishing plans which include the launch of 20 new products by the end 6 December 2023
Privately-held Californian company Alto Neuroscience has announced encouraging results from its Phase IIa study of ALTO-300 at the 62nd Annual Meeting of the Am 5 December 2023
Boston-based biopharma Karuna Therapeutics has announced the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for KarXT (xanome 30 November 2023
Canada’s Xenon Pharmaceuticals has reported topline results from the Phase II X-NOVA trial, showing the primary efficacy endpoint was not met. 28 November 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.